Clinical Trials in Whittier, California
4 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma+3 more
National Cancer Institute (NCI)1,210 enrolled1149 locationsNCT04267848
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled475 locationsNCT05564377
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled12 locationsNCT07211178
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Phase 2Phase 3
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network378 enrolled361 locationsNCT06616584
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 1Phase 2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Breast CancerMetastatic Breast Cancer
Stemline Therapeutics, Inc.435 enrolled118 locationsNCT05563220
Recruiting
Phase 2Phase 3
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
SWOG Cancer Research Network10,000 enrolled1201 locationsNCT03851445
Recruiting
Phase 2
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center88 enrolled9 locationsNCT04553770
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Phase 2
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Breast NeoplasmsOvarian Neoplasms
GlaxoSmithKline30 enrolled25 locationsNCT04641247
Recruiting
Phase 2
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics200 enrolled31 locationsNCT04986423